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Abstract
Background: Tuberculosis/HIV co-infection is a bidirectional and synergistic combination of two very important
pathogens in public health. To date, there have been limited clinical data regarding mortality rates among
tuberculosis/HIV co-infected patients and the impact of antiretroviral therapy on clinical outcomes in Ethiopia.
This study assessed the incidence and predictors of tuberculosis/HIV co-infection mortality in Southwest
Ethiopia.
Methods: A retrospective cohort study collated tuberculosis/HIV data from Jimma University Teaching Hospital
for the period of September 2010 and August 2012. The data analysis used proportional hazards cox
regression model at P value of ≤ 0.05 in the final model.
Results: Fifty-five (20.2 %) patients died during the study period and 272 study participants contributed 3
082.7 person month observations. Factors including: being aged between 35–44 years (AHR = 2.9; 95 % CI:
1.08–7.6), being a female sex worker (AHR = 9.1; 95 % CI: 2.7–30.7), being bed ridden as functional status
(AHR = 3.2; 95 % CI: 1.2–8.7), and being at World Health Organization HIV disease stages 2 (AHR = 0.2;
95 % CI: 0.06–0.5), 3(AHR = 0.3; 95 % CI: 0.1–0.8) and 4(AHR = 0.2; 95 % CI: 0.04–0.55) were significant
predictors of mortality for tuberculosis/HIV co-infected patients.
Conclusions: Contrary to our expectations, the World Health Organization (WHO) HIV disease stage 1 was
found to be a significant predictor of mortality. Higher mortality rates were observed in WHO disease
stage 1 patients compared to patients in stages 2, 3 and 4. The current study also confirmed and
reaffirmed known significant predictors of the mortality for tuberculosis/HIV co-infected patients including
being 35–44 years, being a female sex worker and being bed ridden functional status. The occurrence of
high death rate among tuberculosis/HIV co-infected cases needs actions to reduce this poor outcome.
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Background
Tuberculosis/HIV (TB/HIV) co-infection causes a
serious bidirectional and synergistic combination of
illness in which HIV promotes the progression of latent
tuberculosis infection to disease, and tuberculosis (TB)
accelerates the progression of HIV disease to poor
prognosis including death [1]. In many circumstances,
HIV has been described as the main reason for failure to
meet TB control targets in high HIV settings, and TB is
a major cause of death among people living with HIV in
similar settings [2]. It is also recognised that individuals
with TB/HIV co-infection are highly likely to develop
active TB disease than individuals without HIV [3]
According to the 2010 World Health Organization HIV
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disease stages (WHO) report on TB profiles for different
countries, Ethiopia was classified as a high burden TB,
a high burden HIV and a high burden Multi-drug resis-
tance TB (MDR-TB) nation [3]. The prevalence of TB
was estimated to be 394 (173–623) per 100 000 popula-
tions including those co-infected with HIV, and there
were 152 030 new cases of which 3 190 were below
15 years of age [2].
Worldwide, TB remains one among the leading causes
of death from an infectious agent. For example, in
2014, an estimated 9.6 million people developed TB, of
which 1.2 million (12 %) were co-infected with HIV [4].
In 2015, 33 % of HIV deaths were due to TB showing
that it is still a leading killer of HIV-positive people
[5]. Different studies have indicated that TB is often
the first manifestation of HIV infection, and it is the
leading cause of death among HIV-infected patients
in Africa [6, 7]. Globally, a third (33 %) of population
living with HIV are infected with TB, and more than
two third (70 %) of TB patients have been reported
to live with HIV in Sub-Saharan Africa [3, 7]. In 2004,
a study conducted in Ethiopia reported a TB/HIV co-
infection prevalence of 18 % ranging from 8.3 % (in Silte
zone) to 35.3 % (in South Omo zone) [8]. In 2015, accord-
ing to the study conducted in south Ethiopia [9], 18.2 % of
the HIV infected patients were found to have tuberculosis.
A wide range of factors that influence TB/HIV co-
infection mortality have been reported. These include:
age, gender, marital status, level of education, religion,
occupation, residence, weight, AIDS staging, TB clinical
presentation and calendar year [10, 11]. Previous studies
have focused mainly on the survival rates of general HIV
patients, giving less attention to TB/HIV co-infected
patients [12–15]. A few studies in Ethiopia have analysed
factors associated with mortality in HIV-infected TB
patients [16, 17] and some studies [18, 19] took into
account drug susceptibility patterns of Mycobacterium
tuberculosis outside Ethiopia. However, these studies
assessed the mortality rates of HIV positive and negative
patients on anti-TB treatment. To date, there have been
limited clinical data regarding mortality rates among
TB/HIV co-infected patients and the impact of antire-
troviral therapy (ART) on clinical outcomes in Ethiopia.
The aim of the current study was to investigate the
mortality rate of TB/HIV co-infected patients who deve-
loped TB after commencing ART in order to gain a
better insight of the associated factors.
Methods
The study was conducted in Jimma University Teaching
Hospital (JUTH), 357 km southwest of Addis Ababa, the
Capital City of Ethiopia. Jimma town is situated in
Oromia region, a region that accounts for the highest
number of HIV infected people in Ethiopia [20]. Jimma
is also located near Gambella, a region that contributes
the highest prevalence rate of HIV in Ethiopia [20]. A
refugee camp located near the study setting zone brings
in a large number of refugees from different African
countries (particularly South Sudan), and the high emi-
gration and immigration from and to Jimma places this
town at a heightened risk of HIV and TB infection and
transmission. Jimma teaching hospital is the largest health
facility in Jimma town, its catchment area comprising a
population of 2 486 155 inhabitants of which 89.69 % are
rural dwellers [21]. The hospital caters for both Jimma
and Gambella zones providing a substantial amount and
important data which were favourable for this study.
A retrospective cohort study was conducted using
JUTH records from September 1, 2010 to August 31
2012. The target population was all patients aged
15 years and above, who were HIV infected, on ART and
developed TB when receiving the care from JUTH.
Death due to any cause was the event. Age, sex,
religion, educational level, marital status, occupation,
residence, number of people living in the household,
accessibility to safe water, accessibility of electricity,
number of bedrooms in the household, functional status,
baseline CD4 cells count, drug regimen, WHO clinical
disease stage, disclosure, risky sexual behaviour, tobacco
smoking and alcohol drinking were the independent
variables. WHO clinical disease staging was defined
based on the current ART guideline for Ethiopia [22]. A
risky sexual behaviour was dichotomized as ‘no’ (has regu-
lar sexual partner in the last three months) and ‘yes’ (has
one or more casual sexual partners in the last three
months). Condom use was also dichotomized as yes if
‘use rarely, sometimes, mostly or always during sexual
intercourse’, and no if ‘never use during sexual inter-
course’. Patients were considered as alcohol consumers
if ‘they drink rarely, sometimes, mostly or always’ in their
lifetime. Similarly, they were considered as cigarette
smokers if ‘they smoke rarely, sometimes, mostly or
always’ in lifetime.
Data extraction was performed between August and
October 2013. A data extraction checklist (Annex I) was
used to collect information from the patient cards, regis-
tration and log books. Data were entered in to Epi-data
and then exported to SPSS version 22.0 for mackintosh
for analysis. Incomplete records were excluded from
analysis. The main end point in this study was death due
to any cause among the TB/HIV co-infected patients.
Individuals defaulted, lost to follow up, transferred out
and survivors at the end of the study period were
considered as censored. Finally, the out-come of each
subject was dichotomized in to censored or event. The
data were cleaned and edited before analysis. Data
editing and exploration was undertaken to exclude odd
codes or items that were illogical.
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The analysis of both descriptive and inferential statis-
tics was conducted. The cohort descriptive statistics
included mean, median, standard deviations, and range
values for continuous data; percentage, frequency tables,
and graphs for categorical data. For the comparison of
time to recovery among the different groups of patients,
Kaplan Meir curve was used. Bivariate and multiple
cox regression model with stepwise variable selection
procedural was used to identify independent predictors of
mortality. The assumption for proportional hazard was
assessed graphically. Variables with P-value of <0.25 in the
bivariate cox regression analysis were considered as candi-
date variables for multiple cox regression analysis. P-value
of ≤5 % was considered significant in the final model.
Results
Baseline socio-demographic and economic characteristics
of the study participants
Table 1 describes baseline socio-demographic and
economic characteristics of the study participants. Two
hundred eighty nine (289) TB/HIV co-infected patients
were registered during September 1, 2010 and August
31, 2012. Complete records of 272 TB/HIV co-infected
patients followed up for a mean of 340 days were in-
cluded in the study. The mean age of the study partici-
pants was 32(±8.53) years with the majority of patients
aged between 25–34 years. More than half (58.3 %) of
the study participants were females. Muslims by religion
and daily labourers by occupation respectively, repre-
sented 58.1 % and 31.6 % of participants. Almost half
(51.5 %) and 60.7 % of participants respectively were for-
mally educated and married. In terms of residence, al-
most 70 % of them were urban dwellers. A significant
proportion (76.1 %) of participants had water and elec-
tricity in their residence and less than five people resided
in the household. A significant number of participants
lived in a single bedroomed (44.5 %) or two bedroomed
(40.5 %) households.
Clinical and behavioural characteristics of the study
participants
Table 2 presents clinical and behavioural characteristics
of the study participants. In the cohort, 176 (64.7 %) par-
ticipants had disclosed about their HIV status to their
closest person such as their sexual partner or the next of
kin. The majority of the patients were on first line ART
regimen, working functional status and WHO stage 3.
About 60 % of the study participants had low CD4 count
(<200 cells/copies) and the median (range) CD4 count
was 172.5 (425) cells/copies. When compared to other
types of TB (extra pulmonary or mixed), pulmonary TB
accounted for the majority (78.3 %) of cases. More than
85 % of patients had accessed the service care as new
TB cases. Nearly 70 % of participants’ sexual partners
were HIV positive and more than 70 % of study partici-
pants had risky behaviours. For example, four out of five
patients (82.7 %) reported not using condoms to protect
themselves from sexually transmissible diseases.
Mortality status of study participants
Figures 1, 2 and 3 respectively present mortality status
of study participants by sex, WHO stage and TB type
Table 1 Baseline socio-demographic characteristics of Tb/HIV
co-infected patients at JUTH, Southwest Ethiopia, 2013
Variable (n = 272) Value Number Percent
Age (in years) 15–24 38 13.9
25–34 140 51.5
35–44 69 25.4
> = 45 25 9.2
Sex Male 114 41.9
Female 158 58.1
Occupation Government employed 48 17.7
NGO* 46 16.9
Farmer 80 29.4
Daily labor 86 31.6
Commercial Sex Worker 12 4.4
Educational status Illiterate 81 29.8
Read and write 51 18.8
Formal education 140 51.4
Religion Orthodox 76 27.9
Muslim 134 49.3
Protestant 50 18.4
Catholic 12 4.4
Marital status Married 165 60.7
Single 58 21.3
Divorced 36 13.2
Widowed 13 4.8
Residence Urban 189 69.5
Rural 83 30.5
Number of people
living with
<5 210 77.2
> = 5 62 22.8
Water Yes 207 76.1
No 65 23.9
Electricity Yes 207 76.1
No 65 23.9
Room 1 121 44.5
2 110 40.4
3 31 11.4
4 10 3.7
*as Non-governmental organizations
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using Kaplan-Meier graphs. A total of 55 (20.2 %) TB/
HIV co-infected patients died during the study period.
In addition, records of three, four and seven participants
showed lost to follow up, defaulting, and transferred out
respectively. The 272 study participants contributed to 3
082.7 person month observations (PMO) to the current
study.
Predictors of mortality in TB/HIV Co-infected patients
during TB treatment
Table 3 presents predictors of mortality in TB/HIV
Co-infected patients during TB/HIV treatment. Bivariate
cox regression analysis showed that the risk of death was
statistically different by age, educational status, occupation
and WHO staging of HIV. After adjustment and checking
the fitness of the model; being aged between 35–44 years,
being a female sex worker (FSW), being a bed ridden
functional status, and being WHO stages 2, 3 and 4 were
independent predictors in the multiple Cox regression
analysis.
Discussion
The current study indicates the occurrence of a signi-
ficant mortality rate (20.2 %) amongst TB/HIV co-
infected patients in JUTH. However, this finding was not
dissimilar to the WHO reports that have shown TB’s
contribution of up to 26 % of HIV mortality elsewhere
[23]. Similar findings have also been echoed by studies
in Ethiopia and Malaysia [16, 24].
Study participants whose ages were between 35–44
years old had nearly 3 times higher risk of (AHR = 2.9,
95 % CI: 1.08–7.6) death than those below 25 years
old, the finding which is similar with a study conducted
in Brazil [10]. Some attribution to this occurrence could
be that older patients are more likely to be diagnosed
with HIV and/or TB late. It is well acknowledged that late
diagnosis facilitates poor prognosis and deaths due to im-
mune deficiency from rapid progression to Acquired Im-
mune Deficiency Syndrome (AIDS) and extra-pulmonary
tuberculosis [25–28]. This has implications for practice
indicating the heightened need for early diagnosis and
treatment of both HIV and TB. Similar to studies
elsewhere [29], the odds of TB/HIV death was 9 times for
CSW compared to other occupation such as government
employees (AHR = 9.1, 95 % CI: 2.7–30.7). This finding is
significantly important for nations health systems, and
may have policy and practice implications in Ethiopia and
elsewhere, including prioritizing this group as a key popu-
lation and addressing their needs and designing more
effectively targeted management.
Regarding functional status, bedridden patients had
three times (AHR =3.2, 95 % CI: 1.2–8.7) increased risk
of mortality than patients recorded being in working
status. This finding was in agreement with another study
conducted in Bahir Dar, Ethiopia [16], where bedridden
patients were reported to be nearly 4 times at risk of
dying than patients in work functional status category
(AHR = 3.88; 95%CI: 2.15–7.02). These findings do not
come as a surprise because patients who are bedridden
have probably been exposed to more infections and have
poorer health outcome with vicious cycle of poorer
immunity, which can lead to patients easily succumbing
to opportunistic infections and death [30]. It is thus
plausible to recommend mandatory and frequent screen-
ing for opportunistic infections and other diseases in
Table 2 Clinical and behavioural characteristics of Tb/HIV
co-infected patients at JUTH, Southwest Ethiopia, 2013
Variable (n = 272) Value Number Percent
Disclosure Yes 176 64.7
No 96 35.3
Function Work 138 50.8
Ambulatory 95 34.9
Bed redden 39 14.3
WHO stage 1 17 6.3
2 67 24.6
3 124 45.6
4 64 23.5
Regimen First line 229 84.2
Second line 43 15.8
CD4 <200 cells/copies 163 59.9
> = 200 cells/copies 109 40.1
Median (range) 172.5 (425) -
TB type Pulmonary 213 78.3
Extra pulmonary 14 5.2
Mixed 45 16.5
Mode of TB entry New 232 85.3
Relapse 27 9.9
Dropout 13 4.8
Partner HIV status Positive 189 69.5
Negative 1 0.4
Unknown 82 30.1
Risky behaviour Yes 191 70.2
No 81 29.8
Condom use Yes 47 17.3
No 225 82.7
Tobacco smoking Yes 126 46.3
No 146 53.7
Alcohol drinking Yes 76 27.9
No 196 72.1
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Fig. 1 Mortality status by sex-This figure presents mortality status of the study participants by sex using Kaplan-Meier. It shows that females died
more than males
Fig. 2 Mortality status by WHO stage- This figure presents mortality status of the study participants by WHO stage using Kaplan-Meier. It shows
that TB/HIV co-infected patients diagnosed as WHO clinical stage 1 died more than WHO clinical stages 2, 3 and 4
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order to institute early and effective management strat-
egies to reduce preventable mortalities.
Similar to the study conducted in Bahir Dar [16], the
Kaplan-Meier graph on mortality status of TB/HIV co-
infection by TB type, indicated that extra pulmonary TB
patients in the current study died more than pulmonary
TB patients. However, the findings of the current study
were not statistically significant in the final model of the
cox regression and we hypothesise that a small sample
size could attribute to this effect.
Patients in WHO stages 2, 3 and 4 compared to stage
1 were found to have lower mortality risk. For example,
the risk of dying in patients diagnosed as WHO HIV
stage 3 was decreased by 70 % (AHR = 0.3; 95 % CI:
0.1–0.8) compared to WHO stage 1 patients. This is
surprisingly uncommon, and contrasts findings from
similar studies [16, 30, 31]. We hypothesise that these
differences could be a result of paradoxical and unmasking
types of TB-associated immune reconstitution inflamma-
tory syndrome (TB-IRIS) [32]. IRIS is a clinical debilitating
condition which occurs after the commencement of
ARTs due to inflammatory responses against pathogens
and presents with high fevers, distress, lymphadenopathy,
meningitis, central nervous system lesions, ascites and
radiological worsening of pulmonary infiltrates [33–35].
We thus argue that, when the patient passes the IRIS
stage, it is likely to live longer than a patient at stage 1
who does not survive IRIS. However, this issue is a new
and unique finding and warrants further research and
exploration.
The major limitations of the current study were data
incompleteness and small sample size. In addition, vari-
ables that could potentially have confounding effects
such as alcohol abuse, income, illicit drug use, drug
resistance, co-morbidities, treatment adherence and
severity of immune suppression were not measured. Due
to limitations in finance and human resources, the
outcome status of defaulted, lost to follow-up and trans-
ferred out patients was not traced. This could have
underestimated the incidence of death and subsequently
affect the mortality estimates.
Conclusions
The findings of the current study have informed new
unexpected predictor of mortality: higher mortality rate
in WHO HIV stage 1 compared to WHO HIV disease
stages 2, 3 and 4. It has also reaffirmed known signi-
ficant predictors of the mortality for TB/HIV co-infected
patients including being 35–44 years, being a CSW and
being at bed ridden functional status. The occurrence of
high death rates among TB/HIV co-infected cases needs
actions to reduce this poor outcome. The findings of the
current study have policy and practice implications and
Fig. 3 Mortality status by Tuberculosis type- This figure presents mortality status of the study participants by tuberculosis type using Kaplan-Meier.
It shows that TB/HIV co-infected patients diagnosed as pulmonary tuberculosis died less than extra-pulmonary tuberculosis
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Table 3 Multiple cox regression predictors of mortality among Tb/HIV patients at JUTH, Southwest Ethiopia, 2013
Variable Tb/HIV Co-infection Status (n = 272) Crude Hazard Ratio (95%CI) Adjusted Hazard Ratio (95 % CI)
Alive, n (%) Died, n (%)
Age in years
15–24 32 (14.7) 114 6 (10.9) 1 1
25–34 (52.5) 48 26 (47.3) 21 1.1 (0.5–2.8) 1.4 (0.6–3.8)
35–44 (22.1) (38.2) 2.2 (0.9–5.4)* 2.9 (1.08–7.6)*
> =45 23 (10.7) 2 (3.6) 0.6 (0.1–2.7) 0.3 (0.05–1.6)
Sex
Male 91 (41.9) 23 (41.8) 1 1
Female 126 (58.1) 32 (58.2) 1.1 (0.7–1.9) 1.7 (0.8–3.5)
Educational status
Illiterate 61 (28.1) 20 (36.4) 1 1
Read and write 39 (18) 12 (21.8) 0.7 (0.3–1.3) 0.9 (0.3–2.4)
Formal education 117 (53.9) 23 (41.8) 0.4 (0.2–0.7)* 0.6 (0.2–1.8)
Occupation
Gov’t employed 40 (18.4) 8 (14.5) 1 1
NGO 37 (17.1) 9 (16.4) 1.1 (0.4–2.9) 0.9 (0.4–2.6)
Farmer 69 (31.8) 11 (20) 1.06 (0.4–2.6) 0.7 (0.3–1.9)
Daily labour 64 (29.5) 22 (40) 2.4 (1.04–5.3)* 2.1 (0.9–4.9)
CSW 7 (3.2) 5 (9.1) 6.7 (2.2–20.9)* 9.1 (2.7–30.7)*
Disclosure
Yes 139 (64.1) 37 (67.3) 1 1
No 78 (35.9) 18 (32.7) 0.7 (0.4–1.1) 0.7 (0.3–1.8)
Function
Work 112 (51.6) 26 (47.3) 1 1
Ambulatory 79 (36.4) 16 (29.1) 0.6 (0.3–1.09) 1.05 (0.5–2.1)
Bed ridden 26 (12) 13 (23.6) 0.5 (0.2–1.05) 3.2 (1.2–8.7)*
WHO stage
1 11 (5.1) 7 (12.7) 1 1
2 55 (25.3) 12 (21.8) 0.3 (0.1–0.9)* 0.2 (0.06–0.5)*
3 101 (46.5) 23 (41.8) 0.4 (0.2–1.02) 0.3 (0.1–0.8)*
4 50 (23.1) 13 (23.7) 0.4 (0.2–1.09) 0.2 (0.04–0.5)*
Tb type
Pulmonary 172 (79.3) 41 (74.5) 1 1
Extra-pulmonary 11 (5.1) 3 (5.5) 0.6(0.3–1.07) 2.6(0.5–12.2)
Mixed 34 (15.6) 11 (20) 1(0.3–3.6) 0.9(0.3–2.7)
Risky behaviour
Yes 153 (70.5) 38 (69.1) 1 1
No 64 (29.5) 17 (30.9) 0.9 (0.5–1.6) 0.8 (0.4–1.9)
Partner HIV status
Positive 150 (69.1) 39 (70.9) 1 1
Negative/Unknown 67 (30.9) 16 (29.1) 1.4 (0.8–2.5) 0.5 (0.2–1.5)
*Statistically significant at P < 0.05
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they call for effective management strategies for TB/HIV
co-infection including improved availability of early
diagnosis and improved availability of ARVs to reduce
this high death rates. Further studies are recommended
with larger sample size in order to obtain comprehensive
predictors of TB/HIV co-infection deaths.
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